TENS and LBP: Transcutaneous Electrical Nerve Stimulation (TENS) and Low Back Pain

Sponsor
University of Hartford (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05812885
Collaborator
(none)
34
3
16

Study Details

Study Description

Brief Summary

Low back pain is a significant public health problem, is very prevalent, and is often characterized by the persistence of symptoms. Unfortunately, substantial improvements in people with chronic low back pain are rare, causing most people to live with the pain. People with chronic low back pain may have an exaggerated pain response to nociceptive input into tissues that are may also cause symptoms distant from the site of the primary symptoms. Historically, these symptoms were thought to be related to pathoanatomic changes to the muscles, ligaments or joints. However, the severity of these structural changes weakly correlates with the clinical presentation and in most cases, is not directly related to diagnostic images findings. Patients with chronic musculoskeletal pain, in general, show signs of local/central sensitization. The central sensitization may appear to be directly correlated with the intensity and duration of pain. Therefore, it is essential to reduce pain intensity and minimize the duration of pain to prevent this from happening.

Pain relief for chronic low back pain patients should be aimed at treatments that reduce central excitability and increase central inhibition. Research into chronic low back pain treatment has demonstrated strong evidence that different types of exercise decrease pain and improve quality of life. However, exercise itself may be painful, and the pain may prevent a person from exercising. Thus, treatments aimed at decreasing pain will improve a person's ability to exercise and participate in activities of daily living.

One treatment aimed at reducing central excitability and increasing central inhibition is transcutaneous electrical nerve stimulation (TENS). TENS is a "non-pharmacological" treatment for pain that is inexpensive, safe, and easy to use. Prior studies show that TENS utilizes opioid receptors both spinally and supraspinally to inhibit nociceptive dorsal horn neurons, reduce excitatory neurotransmitter release and reduce hyperalgesia. Thus, TENS may be particularly useful in people with chronic low back pain for its ability to activate descending inhibitory pathways (reduced in chronic low back pain patients) and to inhibit central excitability (increased in chronic low back pain patients).

Previous studies that have investigated the effects of TENS on pain in low back pain patients have failed to use proper intensities of current, and the assessment of pain was not performed during the peak of the analgesic response. Previous studies show that inadequate intensities do not reduce pain or increase pressure pain thresholds. Further, TENS typically does not affect resting pain, while changes in pressure pain thresholds and pain with movement are reduced. Thus, the current study proposes to assess the effects of TENS on measures of pain, function, and descending inhibition using the maximal tolerable intensity of TENS applied to a large area of the trunk.

Condition or Disease Intervention/Treatment Phase
  • Device: TENS
N/A

Detailed Description

The study will be a simple crossover design with the following three treatments (1) active TENS, (2) placebo TENS or (3) no treatment control randomly assigned. Each subject will receive all 3 interventions in random order.

The following tools will be used to measure pain (Numeric Rating Scale), central excitability (pressure pain thresholds, temporal summation and CPM) and function (sit-to-stand test and repeated trunk flexion).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
34 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Crossover AssignmentCrossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcutaneous Electrical Nerve Stimulation (TENS) and Chronic Low-Back Pain: A Randomized Crossover Trial
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active TENS

Active TENS: 100 Hz, 200 μs at maximal tolerable intensity

Device: TENS
Active TENS

Placebo Comparator: Placebo TENS

Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramps off.

Device: TENS
Active TENS

No Intervention: No TENS

Participants will wear a TENS unit that will be turned off to blind the outcome assessor

Outcome Measures

Primary Outcome Measures

  1. Pain at Rest [3 weeks]

    Pain at Rest Difference Score Pre-intervention and Post Intervention

  2. Pain With Movement [3 weeks]

    Pain With Movement Difference Score Pre-intervention and Post Intervention

Secondary Outcome Measures

  1. Sit-to-Stand Test [3 weeks]

    Five sit-to-stand repetitions will be completed in two trials with an average of two trials for scoring

  2. Repeated trunk flexion [3 weeks]

    From a neutral standing position, the subject will be required to flex to the limit of the range and return to the upright position as fast as tolerable.This activity will be repeated 10 times, and the total procedure will be timed with a stopwatch

  3. Pressure Pain Threshold (PPT) [3 weeks]

    A digital pressure algometer will measure the pain threshold to deep mechanical stimuli.

  4. Heat Pain Threshold (HPT) [3 weeks]

    Superficial heat pain sensitivity will be assessed using a handheld thermode.

  5. Temporal Summation [3 weeks]

    Temporal summation will be induced by a pressure algometer

  6. Conditioned pain modulation [3 weeks]

    A cold pressor test will be used to assess the activation of the conditioned pain modulation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • people who have experienced back pain for at least 3 months

  • and have reported a minimal pain level of 3 on the 0-10 Pain Numerical Rating Scale (NRS)

  • age from 18-60

  • TENS naive or have not used TENS for 5 years.

  • Both men and women may participate in the study

Exclusion Criteria:
  • Serious spinal disorders, such as fractures, tumors, or inflammatory arthritis disease

  • nerve root disorders confirmed by neurological tests;

  • neurological diseases

  • severe cardiorespiratory disease

  • pregnancy

  • skin infection or lesions or change in sensation at the TENS application site

  • cancer

  • cardiac pacemaker

  • allergy to electrodes

  • use of opioids.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Hartford

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Richard Liebano, Associate Professor, University of Hartford
ClinicalTrials.gov Identifier:
NCT05812885
Other Study ID Numbers:
  • 23-03-187
First Posted:
Apr 14, 2023
Last Update Posted:
Apr 14, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2023